Generate Biomedicines, Inc. (GENB)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Generate Biomedicines, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 13.25 | 14.43 | 12.93 | 14.18 | 669,528 |
| Nov 6, 2026 | 12.90 | 13.17 | 12.47 | 13.06 | 632,196 |
| Nov 5, 2026 | 14.00 | 14.11 | 12.46 | 12.57 | 1,303,528 |
| Nov 4, 2026 | 14.27 | 14.34 | 13.40 | 14.16 | 636,720 |
| Nov 3, 2026 | 13.33 | 14.17 | 13.27 | 13.85 | 725,548 |
| Nov 2, 2026 | 14.54 | 14.64 | 13.18 | 13.21 | 745,411 |
| Oct 30, 2026 | 14.86 | 15.63 | 14.25 | 14.46 | 1,170,814 |
| Oct 29, 2026 | 15.45 | 16.46 | 15.32 | 15.77 | 1,762,119 |
| Oct 28, 2026 | 13.87 | 15.39 | 13.71 | 15.38 | 3,940,406 |
| Oct 27, 2026 | 12.35 | 13.39 | 12.20 | 13.21 | 757,436 |
| Oct 26, 2026 | 12.52 | 12.59 | 12.20 | 12.35 | 340,898 |
| Oct 23, 2026 | 12.75 | 12.94 | 12.20 | 12.41 | 308,342 |
| Oct 22, 2026 | 13.00 | 13.37 | 12.54 | 12.79 | 498,911 |
| Oct 21, 2026 | 13.04 | 13.21 | 12.80 | 13.11 | 421,212 |
| Oct 20, 2026 | 12.53 | 13.07 | 12.44 | 12.90 | 523,326 |
| Oct 19, 2026 | 12.20 | 12.85 | 12.12 | 12.56 | 675,260 |
| Oct 16, 2026 | 13.02 | 13.22 | 11.84 | 12.09 | 1,074,983 |
| Oct 15, 2026 | 12.53 | 13.16 | 12.43 | 13.06 | 975,150 |
| Oct 14, 2026 | 12.61 | 12.90 | 12.10 | 12.52 | 1,951,144 |
| Oct 13, 2026 | 13.75 | 13.75 | 12.25 | 12.26 | 937,753 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 ARNOLD FRANCES | Director | Sale | 11.4K | $184.7K | Oct 29, 2026 |
| ARNOLD FRANCES | Director | Sale | 1.0K | $16.0K | Sep 1, 2026 |
 Nally Michael | Chief Executive Officer | Purchase | 20.0K | $240.0K | Mar 4, 2026 |
 Silvers Jason | President & CFO | Purchase | 1.0K | $16.0K | Mar 2, 2026 |
 AFEYAN NOUBAR | Director | Conversion of Derivative | 12.72M | -- | Mar 2, 2026 |
| AFEYAN NOUBAR | Director | Conversion of Derivative | 13.70M | -- | Mar 2, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Flagship Pioneering, LLC | 62.7M | 48.8% | 13F |
FMR LLC · net of 13F· joint filing· may incl. warrants· filed Nov 2026 | 7.2M | 5.6% | 13G |
FMR LLC | 5.2M | 4.1% | 13F |
Capital World Investors | 4.2M | 3.3% | 13F |
BRAIDWELL LP | 3.3M | 2.6% | 13F |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.2M | 1.7% | 13F |
NORGES BANK | 2.1M | 1.6% | 13F |
ARCH Venture Management, LLC | 1.9M | 1.5% | 13F |
BANQUE PICTET & CIE SA | 1.8M | 1.4% | 13F |
HARBOURVEST PARTNERS LLC | 1.7M | 1.3% | 13F |
Insiders
- ARNOLD FRANCESDirector
- Nally MichaelChief Executive Officer
- Silvers JasonPresident & CFO
- AFEYAN NOUBARDirector
- Bancel StephaneDirector
- Mendillo Jane LDirector
- Grous BethChief People Officer
- Vessey RupertDirector
- Lee Laurie AnneChief Medical Officer
- Martin SeanChief Legal Officer & GC
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities.
The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020.
Its headquarters are located in Somerville, Massachusetts.
based on 128.35M shares outstanding
US30d Avg
986.99K
60d Avg
1.10M
90d Avg
1.22M